Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Celcuity Inc. (CELC)

100.15 +0.20 (+0.20%)
As of 12:07:33 PM EDT. Market Open.
Trade CELC on Coinbase
Chart Range Bar
Loading chart for CELC
  • Previous Close 99.95
  • Open 100.00
  • Bid 72.93 x 200
  • Ask 126.66 x 200
  • Day's Range 98.70 - 102.43
  • 52 Week Range 12.48 - 151.02
  • Volume 330,210
  • Avg. Volume 1,298,766
  • Market Cap (intraday) 4.884B
  • Beta (5Y Monthly) 0.12
  • PE Ratio (TTM) --
  • EPS (TTM) -3.90
  • Earnings Date (est.) Aug 13, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 160.64

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

www.celcuity.com

155

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CELC
0.41%
S&P 500 (^GSPC)
8.34%

1-Year Return

CELC
698.64%
S&P 500 (^GSPC)
20.14%

3-Year Return

CELC
814.61%
S&P 500 (^GSPC)
68.69%

5-Year Return

CELC
311.63%
S&P 500 (^GSPC)
72.80%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -46.82M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

145.00
160.64 Average
100.15 Current
175.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/3/2026
Analyst Craig-Hallum
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 189 -> 171

Statistics

View More

Valuation Measures

Annual
As of 6/26/2026
  • Market Cap

    4.88B

  • Enterprise Value

    4.81B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    91.12

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.12%

  • Return on Equity (ttm)

    -275.17%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -192.89M

  • Diluted EPS (ttm)

    -3.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    387.06M

  • Total Debt/Equity (mrq)

    604.28%

  • Levered Free Cash Flow (ttm)

    -110.84M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

100.15 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: